{"filings":[{"id":1693796,"accession_number":"0001193125-26-306222","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-07-16T21:02:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies H1 2026 net loss $98M; BLA submission for peanut patch delayed to Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $98.0M for H1 2026 vs $69.0M for H1 2025; Q2 net loss $50.4M.","Cash and equivalents $174.9M as of June 30, 2026, funding into Q3 2027.","BLA submission for VIASKIN Peanut Patch (ages 4-7) now expected in Q3 2026, previously Q2.","R&D expenses $64.6M in H1 2026, up from $55.2M, driven by clinical trials and BLA prep.","SG&A expenses rose to $25.1M from $14.1M due to commercial infrastructure build."],"consensus_eps_estimate":-0.101,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1600000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334039,"accession_number":"0001193125-26-288533","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-06-29T20:28:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies delays VIASKIN Peanut Patch BLA submission to Q3 2026 after FDA feedback","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA submission for VIASKIN Peanut Patch in children aged 4-7 delayed to Q3 2026.","FDA did not request additional data; feedback focused on CMC and biostatistical data formatting.","Company taking additional time to incorporate FDA input; prior timeline not specified.","Conference call scheduled June 29, 2026 at 5pm ET for investor update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888041,"accession_number":"0001193125-26-259488","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-06-05T20:01:38+00:00","items":["5.02","9.01"],"status":"ready","headline":"DBV Technologies grants CEO Daniel Tassé 4.06M PSUs tied to FDA approval of Viaskin Peanut","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["4,060,000 PSUs awarded to CEO; vesting conditioned on FDA approval of Viaskin Peanut BLA.","First FDA approval of VP (any age) triggers vesting of 2,900,000 PSUs; second approval for a different indication/age triggers 1,160,000 PSUs.","Single BLA covering both age groups deems all performance conditions satisfied.","Vested shares delivered in four equal installments starting July 1, 2028 through January 1, 2030.","PSUs canceled if performance conditions not met by July 1, 2028; continued employment required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833604,"accession_number":"0001193125-26-255414","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-06-03T20:05:31+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"DBVT shareholders approve CEO age limit, authorize ATM share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 39 AGM proposals passed; bylaw amended to cap CEO age at 70 years (Article 15).","Board authorized to issue shares via ATM program without preferential subscription rights (resolution 26).","Delegation to issue shares without preemptive rights in various structures also approved (resolutions 21–25).","CEO compensation policy for 2026 passed with ~27M votes against vs ~163M for (resolution 18).","KPMG reappointed as statutory auditor; financial statements for FY2025 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94096,"accession_number":"0001193125-26-206315","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DBV Technologies grants CEO 1.74M PSUs tied to FDA acceptance of Viaskin Peanut BLAs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,740,000 PSUs granted to CEO Daniel Tassé with grant date May 5, 2026.","50% vests upon FDA acceptance of BLA for ages 4-7; 50% for ages 1-3.","Vesting requires continued employment through July 1, 2028; shares delivered in four installments through Jan 2030.","If FDA accepts single BLA covering both age groups, all PSUs eligible to vest.","Unvested PSUs cancelled if milestones not achieved by July 1, 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94095,"accession_number":"0001193125-26-197921","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies reports Q1 net loss of $47.6M; cash of $229M into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.6M ($0.11 per share) vs $27.1M ($0.26) in Q1 2025; loss per share improved due to equity base from PIPE.","Cash and cash equivalents $229M as of March 31, 2026, up from $194M at year-end 2025; funding into Q2 2027.","R&D expenses rose to $33.4M (from $21.5M) driven by COMFORT Toddlers study, BLA readiness, and pre-commercial inventory build.","SG&A expenses increased to $10.5M (from $5.6M) as company builds U.S. commercial infrastructure ahead of potential launch.","BLA submission for VIASKIN Peanut Patch (ages 4-7) planned H1 2026; toddler BLA H2 2026; Phase 2 THRIVE study in infants planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106215,"accession_number":"0001193125-26-126671","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies FY2025 net loss $147M; cash runway into Q2 2027; BLA on track H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $147M for FY2025, compared to $113.9M in FY2024; diluted EPS -$1.05.","Operating income $5.6M, up from $4.2M; R&D expenses rose to $116.7M due to pre-commercial inventory and clinical costs.","Cash and equivalents $194.2M as of Dec 31, 2025; additional $94M received Jan 2026; funding into Q2 2027.","BLA submission for VIASKIN Peanut Patch in children aged 4-7 years anticipated H1 2026; for toddlers 1-3 years H2 2026.","Appointed Kevin Trapp as CCO and James Briggs as CHRO; Philina Lee nominated to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106214,"accession_number":"0001193125-26-084251","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies reports additional positive Phase 3 VITESSE data for VIASKIN Peanut Patch at AAAAI 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.","24% of placebo group decreased eliciting dose over 12 months vs 6.4% of treated group, indicating reduced sensitization.","VIASKIN Peanut Patch was well tolerated; most adverse events were mild local application site reactions.","Company plans to submit Biologics License Application (BLA) to FDA in the first half of 2026.","All sensitivity analyses significant; response rate difference exceeded prespecified 15% threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106213,"accession_number":"0001193125-26-015592","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies secures €166.7M from full exercise of warrants after positive VITESSE trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["€166.7M gross proceeds from full exercise of ABSA Warrants (34.1M) and BS Warrants (71.0M) issued March 2025.","Proceeds to fund BLA submission and U.S. launch preparations for VIASKIN Peanut patch in children 4-7 years if approved.","Company expects to be funded for at least 12 months, including through potential commercial launch.","Exercise triggered by positive VITESSE Phase 3 topline results announced December 16, 2025; no warrants remain outstanding.","59.7M new ordinary shares issued; additional pre-funded warrants may access up to 154M new shares in future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122500,"accession_number":"0001193125-25-320901","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies reports positive Phase 3 VITESSE results; BLA submission on track for H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VITESSE met primary endpoint: response rate 46.6% vs 14.8% placebo (p<0.001); lower bound CI 24.5% >15% threshold.","Safety consistent with prior studies: low discontinuations (3.2% active vs 0.5% placebo), no treatment-related SAEs.","BLA submission for 4-7 year olds planned for first half 2026; prior FDA Breakthrough Therapy Designation.","Positive results trigger acceleration of ABSA and BS warrants exercise period through Jan 15, 2026.","654 children enrolled, largest food allergy immunotherapy trial; compliance 96.2%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122499,"accession_number":"0001193125-25-258780","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"DBV Technologies appoints Philina Lee to Board of Directors effective October 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee replaces Daniel Soland; appointment subject to shareholder ratification at next annual meeting.","She previously served as Chief Commercial Officer of Blueprint Medicines, leading AYVAKIT launch.","Lee will serve on the Compensation Committee of the Board.","She will receive an annual retainer of €100,000 plus €5,000 for committee service.","Company now has ten board members; Lee brings biopharma commercialization experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122498,"accession_number":"0001193125-25-253968","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies Q3 net loss $33.2M; cash $69.8M, runway into Q3 2026 but going concern doubt persists","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.2M in Q3 2025 ($0.24/share); nine-month loss $102.1M ($0.82/share), wider than prior year.","Cash and equivalents $69.8M as of Sep 30; raised ~$30M via ATM in Oct 2025, extending runway into Q3 2026.","Company states cash not sufficient for 12 months; substantial doubt about going concern; seeking additional financing.","VITESSE Phase 3 topline expected Q4 2025; triggering warrant acceleration if primary endpoint met."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":4991000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139198,"accession_number":"0001193125-25-207507","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Board member Daniel Soland resigns from DBV Technologies effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Soland resigned from DBV's Board and Compensation Committee effective immediately on September 18, 2025.","Resignation not due to any dispute or disagreement with the Company or Board.","Board now has 9 remaining members; Nomination and Governance Committee to evaluate filling vacancy.","Soland had served on the Board since 2015; Chairman Michel de Rosen thanked him for his commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139197,"accession_number":"0001193125-25-197277","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies establishes $150M ATM equity program via Citizens JMP; up to 50% dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM program allows sale of up to $150M in ADSs (each representing 5 ordinary shares) on Nasdaq through Citizens JMP.","Proceeds to fund BLA, potential launch of VIASKIN Peanut patch in toddlers aged 1-3, and pipeline development.","Maximum potential dilution of approximately 50% based on shareholder authorization of 136,948,870 ordinary shares.","Prior ATM program dated May 2, 2022 terminated; new program similar terms with 3% commission to agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139196,"accession_number":"0001193125-25-168148","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Tech Q2 2025 net loss $41.9M; cash $103.2M; going concern doubt persists","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss of $41.9M vs $33.1M in Q2 2024, driven by R&D spend on COMFORT Toddlers study.","Cash and cash equivalents $103.2M at June 30, 2025, up from $32.5M at Dec 31, 2024 after $125.5M financing.","Company expects cash runway into Q2 2026; substantial doubt about going concern remains.","Warrant exercise could add up to $181.4M; VITESSE Phase 3 primary endpoint would accelerate exercise period.","No product revenue; operating income solely from R&D tax credit ($2.2M H1 2025 vs $2.6M H1 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":2217000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156751,"accession_number":"0001193125-25-146994","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV Technologies screens first subject in Phase 3 COMFORT Toddlers study for Viaskin Peanut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject screened at Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein as PI.","Study to enroll ~480 subjects at 80-90 centers across U.S., Canada, Australia, UK, and Europe.","BLA submission to FDA anticipated in 2H 2026 under Accelerated Approval Pathway.","Study supplements safety data from Phase 3 EPITOPE; 6-month DBPC phase + optional 18-month open-label."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156750,"accession_number":"0001193125-25-139137","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"DBV Technologies shareholders approve all proposals; CEO receives $498k in variable and exceptional bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2024 ex-post compensation for CEO Daniel Tassé: $348,000 variable comp and $150,000 exceptional bonus.","CFO Virginie Boucinha granted $67,455 exceptional bonus; CMO Pharis Mohideen granted $113,557.","Bylaws amended: Article 11 allows board decisions by written consultation; Article 13 sets chairman age limit at 80.","All 39 resolutions at the Annual General Meeting passed, including reappointment of directors de Rosen, Morris, and Soland.","Delegation to issue shares via ATM program and other capital increases approved; share buyback authorized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156749,"accession_number":"0001193125-25-107505","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Tech Q1 cash $13M, net loss $0.26/share; new $306.9M financing to fund into June 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash used in operations $19.7M; cash balance fell to $13.0M as of March 31, 2025 from $32.5M.","Net loss of $27.1M ($0.26 per share) vs. $27.3M ($0.28) in Q1 2024.","On March 27, 2025, announced up to $306.9M financing; $125.5M received April 7, 2025.","Company expects cash runway into June 2026, but going concern uncertainty remains.","Operating expenses down 8.7% to $27.4M, driven by lower G&A from 2024 office moves."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":753000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175160,"accession_number":"0001193125-25-068727","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"DBV Technologies raises up to $306.9M via private placement for Viaskin Peanut BLA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds up to $306.9M: $125.5M upfront plus up to $181.4M if all warrants exercised.","Immediate dilution of 22.4%; maximum dilution of 73.7% if all warrants exercised.","Existing cash only sufficient into April 2025; with upfront proceeds, cash runway extended to June 2026.","VITESSE Phase 3 results expected Q4 2025; warrant exercise period accelerates if primary endpoint met.","Proceeds to fund BLA submission and commercial launch readiness for Viaskin Peanut in 4-7 year olds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175159,"accession_number":"0001193125-25-060850","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"DBVT: FDA agrees on safety data for Viaskin BLA in 4-7 yr olds; cash only into Apr 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligns: safety data from VITESSE Phase 3 and OLE sufficient for BLA; no COMFORT Children study needed; BLA filing 1H 2026, potential launch acceleration ~1 year.","VITESSE Phase 3 topline results on track for Q4 2025; 654 participants enrolled, largest peanut allergy trial in 4-7 age group.","Cash $32.5M at Dec 31, 2024 (vs $141.4M); net loss $113.9M ($1.17 diluted EPS); operating expenses $120.7M.","Going concern: cash expected only into April 2025; company actively seeking additional capital and reviewing financing options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175158,"accession_number":"0001193125-25-003574","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DBV Technologies reports positive 3-year EPITOPE OLE data; 68.2% passed food challenge at month 36","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["68.2% of toddlers completed oral food challenge (~12-14 peanut kernels) without meeting stopping criteria at month 36, vs 30.7% at month 12.","83.5% reached eliciting dose ≥1000 mg after three years on Viaskin Peanut, up from 64.2% at month 12.","No treatment-related anaphylaxis or serious TEAEs occurred in year 3; local application-site reactions decreased vs earlier years.","New wear-time analysis: subjects with average daily wear time ≥20 hours (68.4% of active group) showed 75.7% responder rate vs 47.3% for <20 hours.","Data presented at Eastern Food Allergy & Comorbidity Conference; investor webcast on Jan 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192094,"accession_number":"0001193125-24-281283","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DBV Tech amends CMO and CFO employment agreements to add change-in-control severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMO Pharis Mohideen eligible for 24 months base salary + 1x target annual bonus lump sum upon CIC termination.","CMO also eligible for equity bonus on unvested awards and COBRA premium coverage for up to 24 months.","CFO Virginie Boucinha eligible for 12 months gross remuneration (base salary) as CIC severance indemnity.","Boucinha CIC agreement void if change in control not completed by December 4, 2025.","Amendments approved by Board; effective December 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192093,"accession_number":"0001193125-24-279571","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DBV Technologies regains Nasdaq minimum bid price compliance on Dec 13, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter on Dec 13, 2024 confirming compliance with Rule 5550(a)(2).","Closing bid price of ADS was at $1.00+ for 10 consecutive business days (Nov 29 - Dec 12, 2024).","Company avoided delisting from Nasdaq for failure to meet minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192092,"accession_number":"0001193125-24-275646","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DBV gains FDA alignment on Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed Phase 3 EPITOPE efficacy data serves as intermediate endpoint for Accelerated Approval.","COMFORT Toddlers safety study on-track for 2Q 2025 start; will enroll ~480 subjects at 80-90 centers.","Post-marketing confirmatory study criteria agreed; BLA submission for toddlers anticipated 2H 2026.","Commercial Viaskin Peanut patch (used in 304 subjects OLE) deemed different product; no safety/efficacy differences vs clinical patch.","Adhesion will be exploratory endpoint in COMFORT Toddlers, not co-objective; wear time data methodology aligned with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192091,"accession_number":"0001193125-24-255153","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"DBV Technologies plans 1-for-5 ADS reverse split effective Nov 29 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 5 ordinary shares.","Effective on or about November 29, 2024; mandatory surrender of certificated ADSs.","Intended to enable DBV to regain compliance with Nasdaq minimum bid price requirement.","No impact on underlying ordinary shares; fractional ADS entitlements sold and cash distributed.","Company gives no assurance that reverse split will satisfy Nasdaq requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192090,"accession_number":"0001193125-24-252203","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies reports Q3 cash $46.4M; going concern doubt, cash runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $90.9M for 9M ended Sep 30 2024 vs $61.5M prior year; Q3 net loss $30.4M.","Cash and cash equivalents $46.4M as of Sep 30 2024, down from $141.4M at Dec 31 2023.","Operating cash burn $92.2M in 9M 2024; company expects cash to fund ops only into Q1 2025.","Substantial doubt about ability to continue as going concern; seeks additional capital.","R&D expenses surged to $70.4M in 9M 2024 ($47.4M prior year) driven by VITESSE Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":3640000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192089,"accession_number":"0001193125-24-241114","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"DBV gets FDA Accelerated Approval path for Viaskin Peanut patch in toddlers; cash $46.4M, going concern doubt","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed Accelerated Approval pathway for Viaskin Peanut patch in 1-3 year-olds; COMFORT safety study (n=300-350) to start Q2 2025.","VITESSE Phase 3 study in 4-7 year-olds enrolled 654 subjects; topline results expected Q4 2025.","EMA scientific advice confirms MAA path for 1-7 year-old indication in Europe using the modified patch.","Preliminary cash at Sep 30, 2024: $46.4M (down from $66.2M); Q3 net cash burn $19.8M.","Substantial doubt about going concern; cash expected to fund operations only into Q1 2025; additional capital needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208583,"accession_number":"0001193125-24-223743","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV completes VITESSE Phase 3 screening early; topline data expected Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Screening closed in August 2024, ahead of schedule; enrollment exceeded original goal.","VITESSE enrolled >600 peanut-allergic children ages 4-7 across 86 sites in U.S., Canada, Europe, UK, Australia.","Subjects randomized 2:1 to active Viaskin Peanut Patch vs placebo; 12-month study.","Largest immunotherapy trial in peanut allergy; DBV targets Biologic License Application submission after data.","Topline efficacy and safety results from VITESSE expected by Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208582,"accession_number":"0001193125-24-188937","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV reports Q2 net loss $33.1M, cash $66.2M, going concern doubt; VITESSE on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $33.1M (US GAAP), basic EPS -$0.34 vs -$0.26 in Q2 2023.","Cash and equivalents $66.2M at June 30, 2024, down from $141.4M at Dec 31, 2023; cash runway extended into Q1 2025.","Substantial doubt about going concern; expects to need additional capital to fund operations.","VITESSE Phase 3 enrollment in 4-7-year-olds on track to complete screening by end of Q3 2024.","Submitted labeling proposal to FDA for COMFORT Toddlers (1-3-year-olds) using EPITOPE data to identify responders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":2568000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226295,"accession_number":"0001193125-24-163393","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DBVT granted second 180-day compliance period for Nasdaq bid-price rule; transfer to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq transferred DBVT ADS listing from Global Select to Capital Market tier effective June 20, 2024.","Second compliance period runs until December 16, 2024 to regain $1.00 minimum bid price.","Compliance requires closing bid price ≥$1.00 for 10 consecutive business days.","Failure to cure could lead to delisting; company may request a hearing to stay suspension.","ADSs continue trading under symbol DBVT; no impact on trading noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226294,"accession_number":"0001193125-24-151728","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"DBV Technologies delays ADS ratio change to June 7, 2024; 1-for-2 reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio change expected effective June 7, 2024, previously planned June 3.","New ratio: 1 ADS = 1 ordinary share, replacing current 1 ADS = 1/2 share (effective 1-for-2 reverse split).","Change intended to help regain Nasdaq minimum bid price compliance; no assurance it will succeed.","No impact on underlying ordinary shares; fractional ADS entitlements to be sold and proceeds distributed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226293,"accession_number":"0001193125-24-141809","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"DBV Technologies plans 1-for-2 reverse ADS split effective June 3 to meet Nasdaq bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1 ADS = 1/2 ordinary share to 1 ADS = 1 ordinary share.","Effective date on or about June 3, 2024; every two existing ADSs exchanged for one new ADS.","No impact on underlying ordinary shares; no fractional new ADSs will be issued.","Intent is to regain compliance with Nasdaq minimum bid price requirement.","Company gives no assurance that the split will result in meeting or maintaining the bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226292,"accession_number":"0001193125-24-140531","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"DBV Technologies shareholders approve reverse split and ATM program at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved a 10:1 reverse split (par value to €1); 46.6M for, 2.3M against.","Approved delegation to board for an 'at-the-market' equity program without pre-emptive rights.","All 7 director renewals passed; votes for ranged from 39.2M to 48.7M.","Registered office changed to 107 avenue de la République, 92320 Châtillon, France.","38 of 38 proposals approved, including capital increases and stock-option grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226291,"accession_number":"0001193125-24-133209","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies reports Q1 net loss $27.3M; cash runway only through Dec 2024, substantial doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $101.5M as of March 31, down from $141.4M at Dec 31, 2023.","Net loss of $27.3M ($0.28 per share) vs $20.6M loss in Q1 2023, driven by R&D spending on VITESSE.","Operating cash burn $34.7M in Q1 2024; company warns cash insufficient for 12 months, requires additional capital.","VITESSE Phase 3 enrollment on track to screen last patient by Q3 2024; 86 sites in US, Canada, Europe, UK, Australia.","Appointed Robert Pietrusko as Chief Regulatory Officer; he led over 35 BLA/NDA/MAA approvals globally."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1407000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245336,"accession_number":"0001193125-24-063634","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DBV Technologies files 2023 Annual Report (10-K) and Universal Registration Document","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Annual Report on Form 10-K for year ended Dec 31, 2023 filed with SEC.","Universal Registration Document filed with French market authority (AMF).","Documents available on company website, SEC.gov, and AMF-france.org.","No financial results or new business developments disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245335,"accession_number":"0001193125-24-062338","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies reports FY2023 net loss $72.7M; cash $141.4M; substantial doubt about going concern","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.7M ($0.76/share) vs $96.3M in 2022; operating expenses $92.2M, with R&D $60.2M.","Cash and equivalents $141.4M as of Dec 31, 2023, down from $209.2M; projected to fund operations only through Dec 31, 2024.","VITESSE Phase 3 trial for ages 4-7: last patient screening expected Q3 2024; COMFORT Toddlers and Children safety trials to initiate.","Substantial doubt about ability to continue as going concern; company intends to seek additional debt and equity capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262794,"accession_number":"0001193125-23-301725","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DBV Technologies receives Nasdaq deficiency notice for ADS bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Dec 20, 2023: DBVT ADS bid price below $1.00 for 30 consecutive business days.","Company has 180 days (until June 17, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, may qualify for additional 180-day period if meeting other listing standards and intending reverse split.","Company will monitor bid price and evaluate options to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262793,"accession_number":"0001193125-23-274580","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DBV reports positive 2-year OLE results for Viaskin Peanut in toddlers; 81.3% reach 1,000 mg eliciting dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.","55.9% completed the 3,444 mg DBPCFC without meeting stopping criteria, up from 30.7% at 12 months.","No treatment-related anaphylaxis or serious TEAEs in second year; local application site reactions decreased.","Placebo crossover group (12 months VP250) showed 62.7% reaching >=1,000 mg ED; single anaphylaxis event.","Results to be presented at ACAAI Nov 11; investor call/webcast Nov 9 at 5pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262790,"accession_number":"0001193125-23-271353","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K/A","filed_at":"2023-11-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DBV Technologies appoints Virginie Boucinha as CFO with base salary of €295,000 and bonus target of 40%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Virginie Boucinha appointed CFO effective November 6, 2023, succeeding Sébastien Robitaille who departed.","Annual base salary of €295,000 with performance bonus target of 40% of base salary.","Eligible for future grant of option to purchase 113,000 shares and 19,000 restricted share units pending Board approval.","Employment is at-will; standard confidentiality, dispute resolution, and indemnification agreements required.","Offers details filed as amendment to prior 8-K reporting the CFO transition and compensatory arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262789,"accession_number":"0001193125-23-268860","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K/A","filed_at":"2023-11-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DBV Technologies CFO departure terms: $400K severance, RSU vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Sébastien Robitaille will depart; serves until Nov 17, 2023.","Separation agreement: $400K severance, $92K bonus portion, 3-month medical.","35,000 RSUs vest on Oct 13, 2023 under agreement.","Mutual releases and non-disparagement covenants included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262792,"accession_number":"0001193125-23-267275","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"DBV reports Q3 net loss, $149M cash; FDA clarifies COMFORT studies; terminates Nestlé deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA provided written feedback harmonizing COMFORT Toddlers/Children protocol design; COMFORT Toddlers uses same eligibility as EPITOPE (DBPCFC required).","Cash $149.1M (Dec 31 2022: $209.2M); 9M 2023 net loss $61.5M ($0.65/share) vs $57.0M loss in 9M 2022.","Terminated Nestlé collaboration (MAG1C atopy patch test) effective Oct 30, 2023; APTITUDE study ended; no further milestones.","First COMFORT Toddlers subject enrollment expected Q1 2024; COMFORT Children start after VITESSE recruitment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":6853000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262791,"accession_number":"0001193125-23-256912","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"DBV Technologies appoints Virginie Boucinha as CFO replacing Sébastien Robitaille","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Virginie Boucinha appointed CFO effective Nov 6, 2023; reports to CEO Daniel Tassé.","Sébastien Robitaille departs on Nov 17, 2023 to pursue other opportunities; two-week transition.","Boucinha brings ~30 years pharma experience, most recently Group Performance Director at Pierre Fabre.","Prior roles at Sanofi include Chief of Staff to CEO and Global Transformation Office Head.","Company advancing two BLAs for Viaskin in toddlers and children with peanut allergy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279985,"accession_number":"0001193125-23-199395","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FDA aligns with DBV on COMFORT safety study designs for toddlers (1-3) and children (4-7); cash $174M, H1 loss $44.8M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on COMFORT Toddlers design: 6-month, 3:1 randomization, ~400 subjects, ages 1-3, no oral food challenge required.","FDA feedback on COMFORT Children (ages 4-7) consistent with Dec 2022 agreement; studies target ~600 on active treatment per group.","Cash and equivalents $174M as of June 30, 2023 (down from $209.2M at Dec 31, 2022); H1 net loss $44.8M ($0.48/share).","Operating expenses $50.7M in H1 (+$6.1M YoY); R&D up to $33.6M driven by VITESSE trial initiation in March 2023.","Company raised $7.8M via ATM in June 2023; EPITOPE data published in NEJM in May 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298490,"accession_number":"0001193125-23-141488","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.","Treatment responder rates: 67.0% for Viaskin Peanut vs 33.5% for placebo after 12 months.","No FDA-approved treatment options exist for peanut-allergic children under 4 years; DBV is advancing regulatory efforts for this age group.","Viaskin Peanut was well-tolerated with low rates of treatment-related anaphylaxis and epinephrine use; local application site reactions decreased over time.","Editorial in NEJM called the data 'very good news' for toddlers with peanut allergy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298489,"accession_number":"0001193125-23-136025","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DBV Technologies Q1 net loss widens to $20.5M; cash drops to $192.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $192.3M as of March 31, 2023, down from $209.2M at Dec 31, 2022.","Net loss of $20.5M for Q1 2023 vs $16.7M loss in Q1 2022; loss per share $0.22.","R&D expenses rose 31% to $16.0M, driven by initiation of VITESSE trial in March 2023.","Cash used in operations $20.8M vs $1.5M in Q1 2022; prior year included $20.9M French R&D tax credit receipt.","Total operating expenses $23.3M, up 21% from $19.3M in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":2194000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298488,"accession_number":"0001193125-23-106920","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"DBV gets FDA path for Viaskin Peanut BLA in toddlers 1-3; EPITOPE efficacy confirmed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed Phase 3 EPITOPE met primary endpoint; no additional efficacy study required.","FDA requires new safety study in ~600 toddlers to augment safety data; no food challenge needed.","Company to submit safety study protocol to FDA by end of Q2 2023; Human Factors study and CMC work ongoing.","Cash and cash equivalents $192.3M as of March 31, 2023 (down $16.9M from Dec 31, 2022).","Viaskin Peanut in 1-3 and 4-7 year-olds remain separate product candidates with independent paths."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298487,"accession_number":"0001193125-23-099942","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DBV Technologies shareholders approve all 41 proposals at 2023 Annual General Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 41 proposals at the April 12, 2023 Annual General Meeting were approved by shareholders.","Directors Danièle Guyot-Caparros, Maïlys Ferrère, Daniel Tassé, and Michael J. Goller were re-elected.","Share issuance authorities granted, including an ATM program and a 10% annual capital increase limit.","Board authorized to buy back shares up to 10% of capital per year.","Bylaw amendments to Articles 11, 18, 20, 21, and 23 were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318696,"accession_number":"0001193125-23-067816","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"DBV Technologies confirms no cash deposits at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it holds no cash deposits or securities at Silicon Valley Bank.","Disclosure follows SVB collapse; no financial exposure to SVB.","No impact on DBV's cash position or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318695,"accession_number":"0001193125-23-063077","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DBV screens first patient in VITESSE Phase 3 peanut allergy trial for ages 4–7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois for VITESSE Phase 3 trial.","Trial enrolls 600 children ages 4–7, randomized 2:1 active (Viaskin Peanut 250 µg) vs placebo.","Primary efficacy endpoint is treatment response rate at Month 12; last patient screening expected 1H 2024.","Topline results anticipated in 1H 2025; FDA supports study to potentially support BLA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318694,"accession_number":"0001193125-23-058479","cik":1613780,"company_name":"DBV Technologies S.A.","ticker":"DBVT","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"DBV Technologies FY2022 net loss $96.3M; cash $209.2M after $180.4M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $96.3M ($1.24 per share) vs $97.8M ($1.78) in 2021; operating expenses down 3% to $101.5M.","Cash and cash equivalents $209.2M at Dec 31, 2022, up from $77.3M, driven by $180.4M PIPE and $14.1M ATM.","Completed EVOLVE user experience study of modified Viaskin Peanut patch in 50 children ages 4-11; positive ease of use.","R&D expenses increased 7% to $75.5M; average employees reduced to 86 from 101 due to restructuring.","Research tax credit reimbursement of $26.1M received in 2022 for years 2019-2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":953713609.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-03T23:59:59+00:00|318694"}